Managing Azathioprine-Induced Myelosuppression and Alopecia Totalis: Lessons from a SLE Patient
Introduction Azathioprine (AZA), an immunosuppressant and mercaptopurine analog, is used to manage rheumatological and immunological conditions. Although effective, AZA can cause myelosuppression, sometimes necessitating dose adjustments or discontinuation. While severe pancytopenia or alopecia is r...
Saved in:
| Main Authors: | Saumya Dinithi Rupasinghe, Duminda Abeysinghe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
World Scientific Publishing
2024-01-01
|
| Series: | Journal of Clinical Rheumatology and Immunology |
| Online Access: | https://www.worldscientific.com/doi/10.1142/S2661341724740936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alopecia as the first manifestation of azathioprine myelosuppression in a genetically predisposed patient
by: Debashish Mishra, et al.
Published: (2019-01-01) -
Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis
by: Taiyo Hitaka, et al.
Published: (2025-07-01) -
A Novel Hope for Alopecia Totalis Patients: Case Report
by: Manal Elsayed, et al.
Published: (2020-11-01) -
Linezolid-Induced Myelosuppression
by: Kristiana Jordan, et al.
Published: (2024-08-01) -
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine
by: Évelyne Vinet, et al.
Published: (2021-04-01)